T
Thomas E. Prisinzano
Researcher at University of Kentucky
Publications - 190
Citations - 5968
Thomas E. Prisinzano is an academic researcher from University of Kentucky. The author has contributed to research in topics: Salvinorin A & Agonist. The author has an hindex of 46, co-authored 178 publications receiving 5353 citations. Previous affiliations of Thomas E. Prisinzano include Scripps Research Institute & Rockefeller University.
Papers
More filters
Journal ArticleDOI
An Opioid Agonist that Does Not Induce μ-Opioid Receptor—Arrestin Interactions or Receptor Internalization
Chad E. Groer,Kevin Tidgewell,Robert A. Moyer,Wayne W. Harding,Richard B. Rothman,Thomas E. Prisinzano,Laura M. Bohn +6 more
TL;DR: Evaluating μOR trafficking in response to activation by a novel μ-selective agonist derived from the naturally occurring plant product, salvinorin A, finds that this compound, termed herkinorin, does not promote the recruitment of β-arrestin-2 to the μOR and does not lead to receptor internalization.
Journal ArticleDOI
Evidence for the Involvement of Dopamine Transporters in Behavioral Stimulant Effects of Modafinil
Dorota Zolkowska,Raka Jain,Richard B. Rothman,John S. Partilla,Bryan L. Roth,Vincent Setola,Thomas E. Prisinzano,Michael H. Baumann +7 more
TL;DR: The data show that modafinil interacts with DAT sites in rat brain, a property shared with agonist medications under investigation for treating cocaine dependence, and suggest that modAFinil should be tested as an adjunct for treating METH addiction.
Journal ArticleDOI
Neoclerodane Diterpenes as a Novel Scaffold for μ Opioid Receptor Ligands
Wayne W. Harding,Kevin Tidgewell,Nathan Byrd,Howard Cobb,Christina M. Dersch,Eduardo R. Butelman,Richard B. Rothman,Thomas E. Prisinzano +7 more
TL;DR: A nonnitrogenous neoclerodane diterpene with mu opioid receptor affinity that is an agonist at mu opioid receptors is reported, which represents the identification of a novel structural class of mu opioids receptor agonists.
Journal ArticleDOI
Gedunin, a Novel Hsp90 Inhibitor: Semisynthesis of Derivatives and Preliminary Structure–Activity Relationships
TL;DR: In an effort to further probe the mechanism of action, 19 semisynthetic derivatives of gedunin were prepared and their antiproliferative activity against MCF-7 and SkBr3 breast cancer cells determined.
Journal ArticleDOI
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity
Lisa K. Brents,Anna Gallus-Zawada,Anna Radominska-Pandya,Tamara Vasiljevik,Thomas E. Prisinzano,William E. Fantegrossi,Jeffery H. Moran,Paul L. Prather +7 more
TL;DR: The present study indicates that further work examining the physiological effects of synthetic cannabinoid metabolism is warranted, and suggests that a complex mix of metabolically produced CB1R ligands may contribute to the adverse effect profile of JWH-073-containing products.